• Explore /
  • Poster
  • / Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).

Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).

Abstract Video & Slides Poster

Authors

null

Stephen J. Schuster

Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

Stephen J. Schuster , Jie Zhang , Hongbo Yang , Abhijit Agarwal , Wenxi Tang , Marcela Martinez-Prieto , Vamsi Bollu , Qiufei Ma , David Kuzan , Richard T. Maziarz , Marie José Kersten

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 7535)

DOI

10.1200/JCO.2021.39.15_suppl.7535

Abstract #

7535

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Jonathan Bender

First Author: Alison R. Sehgal

First Author: Jeremy S. Abramson

First Author: Andrew Charles Dietz